Stefan Buettner1, Arthur J A T Braat2, Georgios Antonios Margonis3, Daniel B Brown4, Kevin B Taylor4, Anthony J Borgmann4, S Cheenu Kappadath5, Armeen Mahvash6, Jan N M IJzermans1, Matthew J Weiss3, Angela Lamarca7, Jon K Bell8, Juan W Valle7, Jeroen Hagendoorn9, Bas Groot Koerkamp1, Daniel Y Sze10, Marnix G E H Lam11. 1. Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 2. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Room E.01.1.29, Internal Mail E01.132, P.O. 85500, 3508 GA Utrecht, The Netherlands. 3. Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland. 4. Department of Interventional Radiology, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Medical Oncology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom. 8. Department of Radiology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom. 9. Departments of Surgery, University Medical Center Utrecht, Room E.01.1.29, Internal Mail E01.132, P.O. 85500, 3508 GA Utrecht, The Netherlands. 10. Department of Interventional Radiology, Stanford University Medical Center, Stanford, California. 11. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Room E.01.1.29, Internal Mail E01.132, P.O. 85500, 3508 GA Utrecht, The Netherlands. Electronic address: m.lam@umcutrecht.nl.
Abstract
PURPOSE: To report outcomes of yttrium-90 (90Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with χ2 tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method. RESULTS: Grade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval [CI], 21-37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after 90Y radioembolization (4%). CONCLUSIONS: This study provides observational data of treatment outcomes after 90Y radioembolization in patients with unresectable ICC.
PURPOSE: To report outcomes of yttrium-90 (90Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND METHODS: Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with χ2 tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method. RESULTS: Grade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval [CI], 21-37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after 90Y radioembolization (4%). CONCLUSIONS: This study provides observational data of treatment outcomes after 90Y radioembolization in patients with unresectable ICC.
Authors: Matthias P Fabritius; Najib Ben Khaled; Wolfgang G Kunz; Jens Ricke; Max Seidensticker Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241
Authors: Jessica J Holster; Marouan El Hassnaoui; Stijn Franssen; Jan N M IJzermans; Jeroen de Jonge; Bianca Mostert; Wojciech G Polak; Roeland F de Wilde; Marjolein Y V Homs; Bas Groot Koerkamp Journal: Ann Surg Oncol Date: 2022-03-16 Impact factor: 4.339